HDAC6 and pulmonary fibrosis: Together, these results suggested that tubastatin might have ameliorated bleomycin-induced lung fibrosis by targeting the PI3K-AKT pathway, likely through an HDAC6-independent mechanism, and that tubastatin might have significant off-target effects aside from HDAC6 [235].